Non-steroidal Anti-inflammatory Drugs as Candidates for the Prevention or Treatment of Alzheimer's Disease: Do they Still Have a Role? - PubMed (original) (raw)

Review

Non-steroidal Anti-inflammatory Drugs as Candidates for the Prevention or Treatment of Alzheimer's Disease: Do they Still Have a Role?

Alberto Villarejo-Galende et al. Curr Alzheimer Res. 2020.

Abstract

Purpose of review: To provide an updated analysis of the possible use of non-steroidal anti-inflammatory drugs (NSAIDs) as treatments for Alzheimer´s disease (AD).

Recent findings: Neuroinflammation in AD is an active field of research, with increasing evidence from basic and clinical studies for an involvement of innate or adaptive immune responses in the pathophysiology of AD. Few clinical trials with anti-inflammatory drugs have been performed in the last decade, with negative results.

Summary: Besides the information gathered from basic research, epidemiological studies have provided conflicting findings, with most case-control or prevalence studies suggesting an inverse relationship between NSAIDs use and AD, but divided results in prospective population-based incident cohort studies. Clinical trials with different NSAIDs are almost unanimous in reporting an absence of clear benefit in AD.

Conclusion: The modulation of inflammatory responses is a promising therapeutic strategy in AD. After three decades of research, it seems that conventional NSAIDs are not the best pharmacological option, both for their lack of clear effects and for an unfavorable side-effect profile in long-term treatment. The development of other anti-inflammatory drugs as candidate treatments in AD may benefit from the knowledge acquired with NSAIDs.

Keywords: Alzheimer´s disease; NSAIDs; amyloid; anti-inflammatory drugs; clinical trials; risk.

PubMed Disclaimer

Cited by

Longitudinal cerebrospinal fluid measurements show glial hypo- and hyperactivation in predementia Alzheimer's disease.
Nordengen K, Kirsebom BE, Richter G, Pålhaugen L, Gísladóttir B, Siafarikas N, Nakling A, Rongve A, Bråthen G, Grøntvedt GR, Gonzalez F, Waterloo K, Sharma K, Karikari T, Vromen EM, Tijms BM, Visser PJ, Selnes P, Kramberger MG, Winblad B, Blennow K, Fladby T. Nordengen K, et al. J Neuroinflammation. 2023 Dec 13;20(1):298. doi: 10.1186/s12974-023-02973-w. J Neuroinflammation. 2023. PMID: 38093257 Free PMC article.
Potential Use of Agave Genus in Neuroinflammation Management.
Herrera-Ruiz M, Jiménez-Ferrer E, González-Cortazar M, Zamilpa A, Cardoso-Taketa A, Arenas-Ocampo ML, Jiménez-Aparicio AR, Monterrosas-Brisson N. Herrera-Ruiz M, et al. Plants (Basel). 2022 Aug 25;11(17):2208. doi: 10.3390/plants11172208. Plants (Basel). 2022. PMID: 36079590 Free PMC article. Review.
From the Bush to the Brain: Preclinical Stages of Ethnobotanical Anti-Inflammatory and Neuroprotective Drug Discovery-An Australian Example.
Kumar P, Mathew S, Gamage R, Bodkin F, Doyle K, Rossetti I, Wagnon I, Zhou X, Raju R, Gyengesi E, Münch G. Kumar P, et al. Int J Mol Sci. 2023 Jul 4;24(13):11086. doi: 10.3390/ijms241311086. Int J Mol Sci. 2023. PMID: 37446262 Free PMC article. Review.
Neuroinflammation represents a common theme amongst genetic and environmental risk factors for Alzheimer and Parkinson diseases.
Boyd RJ, Avramopoulos D, Jantzie LL, McCallion AS. Boyd RJ, et al. J Neuroinflammation. 2022 Sep 8;19(1):223. doi: 10.1186/s12974-022-02584-x. J Neuroinflammation. 2022. PMID: 36076238 Free PMC article. Review.
Targeting RIPK1 kinase for modulating inflammation in human diseases.
Li W, Yuan J. Li W, et al. Front Immunol. 2023 Mar 8;14:1159743. doi: 10.3389/fimmu.2023.1159743. eCollection 2023. Front Immunol. 2023. PMID: 36969188 Free PMC article. Review.

Non-steroidal Anti-inflammatory Drugs as Candidates for the Prevention or Treatment of Alzheimer's Disease: Do they Still Have a Role? - PubMed (original) (raw)